Sertraline vs Paroxetine: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Sertraline inhibits the serotonin transporter with moderate selectivity, plus weak dopamine transporter and sigma-1 receptor activity. CTD documents 147 gene interactions — broader than paroxetine's 51 — reflecting sertraline's wider receptor engagement. However, sertraline has lower SIADH risk than paroxetine, making its sodium depletion less dangerous. Folate consumption occurs through the same BH4-dependent serotonin synthesis pathway, and melatonin disruption through pineal serotonin-to-melatonin conversion interference.
Sertraline has 44% bioavailability with a 26-hour half-life and 98.5% protein binding, providing stable once-daily dosing with manageable (not severe) discontinuation when tapering.
- ✓Lower SIADH risk than paroxetine — safer for sodium levels, especially in elderly patients
- ✓Manageable 26-hour half-life creates moderate discontinuation — not the severe syndrome paroxetine causes
- ✓Six FDA indications: depression, OCD, panic, PTSD, social anxiety, PMDD — matching paroxetine's breadth
- ✓Most-prescribed antidepressant in the U.S. with the largest real-world safety dataset
- ✗147 CTD gene interactions — nearly 3x paroxetine's 51 — indicating broader off-target molecular effects
- ✗98.5% protein binding creates displacement risks with highly-bound co-medications
- ✗GI side effects (nausea, diarrhea) more prominent than paroxetine's anticholinergic-mediated constipation
- ✗FAERS logs 67,356 adverse event reports reflecting extremely high prescribing volume
Patients who need broad anxiety-depression coverage with lower sodium depletion risk and manageable discontinuation — the default SSRI for most adults.
Paroxetine is the most potent serotonin reuptake inhibitor in the SSRI class, with additional anticholinergic, histaminergic, and CYP2D6 inhibitory activity. CTD documents 51 gene interactions — fewer than sertraline's 147 — but the interactions are concentrated on high-impact targets including SIADH-related genes that explain paroxetine's uniquely dangerous hyponatremia risk. The potent serotonin transporter binding means more aggressive folate consumption and melatonin disruption per milligram.
Paroxetine has 45% bioavailability with a 17–22 hour half-life, 95% protein binding, and critically — nonlinear pharmacokinetics that make dose changes unpredictable and discontinuation treacherous.
- ✓Most potent serotonin reuptake inhibitor — effective when other SSRIs fail
- ✓Seven FDA indications including unique hot flashes approval (Brisdelle)
- ✓Only 51 CTD gene interactions versus sertraline's 147 — narrower molecular target count
- ✓ChEMBL documents 254 RCTs across 120,623 patients — the most studied SSRI
- ✗Highest SIADH risk of any SSRI — the most dangerous for sodium depletion, especially in elderly patients
- ✗One of the worst SSRI discontinuation syndromes — brain zaps, emotional instability, vertigo from nonlinear kinetics
- ✗Strong CYP2D6 inhibition blocks codeine, tamoxifen, and many co-medications
- ✗Significant weight gain and anticholinergic effects (dry mouth, constipation, cognitive dulling)
Treatment-resistant depression, multiple anxiety disorders, or menopausal hot flashes — reserved for patients who failed sertraline and escitalopram first.
Feature Comparison
| Feature | Sertraline | Paroxetine |
|---|---|---|
| Drug Class | SSRI (moderate selectivity) | SSRI (most potent SRI + anticholinergic) |
| Nutrients Depleted | 3 — sodium, folate, melatonin | 3 — sodium, folate, melatonin |
| CTD Gene Interactions | 147 documented | 51 documented |
| SIADH Risk | Moderate | Highest of any SSRI |
| Half-Life | 26 hours (linear kinetics) | 17–22 hours (nonlinear kinetics) |
| Discontinuation Severity | Moderate (manageable taper) | Severe (brain zaps, vertigo) |
| CYP2D6 Inhibition | Mild | Strong (blocks codeine, tamoxifen) |
| FDA Indications | 6 indications | 7 indications (+ hot flashes) |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both SSRIs deplete the same three nutrients, but the risk profiles diverge on two critical fronts. First, sodium safety: paroxetine carries the highest SIADH risk of any SSRI, making it the most dangerous for hyponatremia — particularly in elderly patients, women, and those on diuretics. Sertraline's moderate SIADH risk is significantly safer. Second, discontinuation: paroxetine's nonlinear 17-hour half-life creates one of the most miserable withdrawal experiences in psychiatry (brain zaps, emotional lability, vertigo), while sertraline's linear 26-hour half-life allows manageable tapering. According to CTD molecular analysis, sertraline has nearly 3x more gene interactions (147 vs 51), but this molecular breadth doesn't translate to worse nutrient depletion — it reflects wider off-target receptor binding. For most patients, sertraline is the safer, more forgiving SSRI. Paroxetine is reserved for treatment-resistant cases where its unmatched serotonin transporter potency is genuinely needed.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 147 gene interactions for sertraline; 51 for paroxetine including SIADH-related pathway genes
- [2]ChEMBL bioactivity database: clinical trial data for sertraline (6 indications); 254 RCTs for paroxetine (120,623 patients, 7 indications)
- [3]FAERS (FDA Adverse Event Reporting System): 67,356 sertraline reports; paroxetine reports with higher SIADH event rates
- [4]PharmGKB pharmacogenomics database: CYP2D6 strong inhibitor classification for paroxetine; mild for sertraline
- [5]PubMed PMID 19185342 — Cipriani A et al. Comparative efficacy and acceptability of 12 new-generation antidepressants. Lancet. 2009;373(9665):746-758
Check your medications
Check Free →